某院右丙亚胺临床应用的合理性调查分析  

Investigation and Assessment on Application of Dexrazone in A Hospital

作　　者：周花萍 曾英彤[1] 陈文颖[1] 杨敏[1] 

机构地区：[1]广东省人民医院药学部,广东广州510080 [2]中山大学药学院,广东广州510006

出　　处：《今日药学》2015年第3期214-217,共4页Pharmacy Today

摘　　要：目的调查分析本院乳腺癌患者右丙亚胺(Dexrazone,DEX)的应用状况,促进临床合理用药。方法回顾2013年本院乳腺癌患者使用DEX患者的病历,参照2008年美国肿瘤化疗及放疗保护剂临床操作指南,对其用药指征、用药时机、用药剂量、用药人群等情况进行分析。结果 2013年本院共228例乳腺癌患者使用DEX,其中早期乳腺癌患者占91.14%,31.14%用于预防非蒽环类药物的心脏毒性,首次应用蒽环类药物即给予DEX的比例高达90.44%,仅3.82%的患者使用DEX时蒽环类药物累积剂量大于300 mg/m2。结论临床应用右丙亚胺存在不合理现象,应提高临床医师对DEX的认识,促进临床合理用药。OBJECTIVE To investigate and analysis the usage of dexrazone in patients with breast cancer in the hospital,and to promote its rational application in the clinic. METHODS The records of breast cancer patients using DEX were reviewed. The medication indication,timing,dosage and crowd in the hospital during 2013 were assessed according to the American Society of Clinical Practice Gudidelines for the Use of Chemotherapy and Radiotherapy protectants 2008. RESULTS A total of 228 cases of malignant breast cancer patients with DEX in the hospital. Of which 91. 14% for early stage breast cancer,31. 14% for the prevention of nonanthracycline cardiotoxicity. Patients received dexrazoxane when given from first dose of anthracycline up to 90. 44%,only 3. 82% of patients using the DEX had received more than 300 mg / m2 of anthracycline. CONCLUSION There are some unreasonable situation in the application of DEX in patients with breast cancer,clinicians should raise awareness of using DEX properly to ensure its safe and effective application.

关 键 词：右丙亚胺 蒽环类药物心脏毒性 乳腺癌 合理用药 

分 类 号：R97[医药卫生—药品]